These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35987253)

  • 1. Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.
    Shiraki A; Oyama JI; Shimizu T; Nakajima T; Yokota T; Node K
    Eur J Pharmacol; 2022 Sep; 931():175194. PubMed ID: 35987253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
    Nambu H; Takada S; Fukushima A; Matsumoto J; Kakutani N; Maekawa S; Shirakawa R; Nakano I; Furihata T; Katayama T; Yamanashi K; Obata Y; Saito A; Yokota T; Kinugawa S
    Eur J Pharmacol; 2020 Jan; 866():172810. PubMed ID: 31738936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.
    Makrecka-Kuka M; Korzh S; Videja M; Vilks K; Cirule H; Kuka J; Dambrova M; Liepinsh E
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):791-797. PubMed ID: 32424653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
    Philippaert K; Kalyaanamoorthy S; Fatehi M; Long W; Soni S; Byrne NJ; Barr A; Singh J; Wong J; Palechuk T; Schneider C; Darwesh AM; Maayah ZH; Seubert JM; Barakat K; Dyck JRB; Light PE
    Circulation; 2021 Jun; 143(22):2188-2204. PubMed ID: 33832341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
    Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
    Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
    Kumar N; Garg A; Bhatt DL; Sabongui S; Gupta N; Chaudhry S; Arena R; Verma S
    Can J Physiol Pharmacol; 2018 Nov; 96(11):1184-1187. PubMed ID: 30265814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.
    Kolwelter J; Bosch A; Jung S; Stabel L; Kannenkeril D; Ott C; Bramlage P; Schiffer M; Achenbach S; Schmieder RE
    ESC Heart Fail; 2021 Dec; 8(6):5327-5337. PubMed ID: 34544205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Empagliflozin: current indications and aspects for daily clinical practice].
    Iacoviello M; Aspromonte N
    G Ital Cardiol (Rome); 2023 Dec; 24(12 Suppl 3):3S-12S. PubMed ID: 38226446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.